These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24135777)

  • 1. HIV-1 disease progression during highly active antiretroviral therapy: an application using population-level data in British Columbia: 1996-2011.
    Nosyk B; Min J; Lima VD; Yip B; Hogg RS; Montaner JS;
    J Acquir Immune Defic Syndr; 2013 Aug; 63(5):653-9. PubMed ID: 24135777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
    Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
    JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study.
    Montaner JS; Lima VD; Barrios R; Yip B; Wood E; Kerr T; Shannon K; Harrigan PR; Hogg RS; Daly P; Kendall P
    Lancet; 2010 Aug; 376(9740):532-9. PubMed ID: 20638713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increase in CD4 cell counts between 2 and 3.5 years after initiation of antiretroviral therapy and determinants of CD4 progression in India.
    Rajasekaran S; Jeyaseelan L; Raja K; Vijila S; Krithigaipriya KA; Kuralmozhi R
    J Postgrad Med; 2009; 55(4):261-6. PubMed ID: 20083872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cohort Profile: HAART Observational Medical Evaluation and Research (HOMER) cohort.
    Patterson S; Cescon A; Samji H; Cui Z; Yip B; Lepik KJ; Moore D; Lima VD; Nosyk B; Harrigan PR; Montaner JS; Shannon K; Wood E; Hogg RS
    Int J Epidemiol; 2015 Feb; 44(1):58-67. PubMed ID: 24639444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
    Lima VD; Harrigan R; Murray M; Moore DM; Wood E; Hogg RS; Montaner JS
    AIDS; 2008 Nov; 22(17):2371-80. PubMed ID: 18981777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment.
    Bratt G; Karlsson A; Leandersson AC; Albert J; Wahren B; Sandström E
    AIDS; 1998 Nov; 12(16):2193-202. PubMed ID: 9833861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load.
    Miller V; Sabin CA; Phillips AN; Rottmann C; Rabenau H; Weidmann E; Rickerts V; Findhammer S; Helm EB; Staszewski S
    AIDS; 2000 Sep; 14(14):2129-36. PubMed ID: 11061654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies.
    Chêne G; Sterne JA; May M; Costagliola D; Ledergerber B; Phillips AN; Dabis F; Lundgren J; D'Arminio Monforte A; de Wolf F; Hogg R; Reiss P; Justice A; Leport C; Staszewski S; Gill J; Fatkenheuer G; Egger ME;
    Lancet; 2003 Aug; 362(9385):679-86. PubMed ID: 12957089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporal trends in the discontinuation of first-line antiretroviral therapy.
    Gonzalez-Serna A; Chan K; Yip B; Chau W; McGovern R; Samji H; Lima VD; Hogg RS; Harrigan R
    J Antimicrob Chemother; 2014 Aug; 69(8):2202-9. PubMed ID: 24739147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort.
    Tanner Z; Lachowsky N; Ding E; Samji H; Hull M; Cescon A; Patterson S; Chia J; Leslie A; Raboud J; Loutfy M; Cooper C; Klein M; Machouf N; Tsoukas C; Montaner J; Hogg RS;
    BMC Infect Dis; 2016 Oct; 16(1):590. PubMed ID: 27769246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A decision tree to help determine the best timing and antiretroviral strategy in HIV-infected patients.
    Piroth L; Fournel I; Mahy S; Yazdanpanah Y; Rey D; Rabaud C; Faller JP; Hoen B; Fardeheb M; Quantin C; Chavanet P; Binquet C;
    Epidemiol Infect; 2011 Dec; 139(12):1835-44. PubMed ID: 21232172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of a World Health Organization first-line regimen (stavudine/lamivudine/nevirapine) in antiretroviral-naïve individuals in a Western setting.
    Tam LW; Hogg RS; Yip B; Montaner JS; Harrigan PR; Brumme CJ
    HIV Med; 2007 Jul; 8(5):267-70. PubMed ID: 17561871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Markov model for the effects of virological failure on HIV/AIDS progression in tuberculosis co-infected patients receiving antiretroviral therapy in a rural clinic in northern South Africa.
    Shoko C; Chikobvu D; Bessong PO
    S Afr Med J; 2020 Mar; 110(4):313-319. PubMed ID: 32657744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire.
    Djomand G; Roels T; Ellerbrock T; Hanson D; Diomande F; Monga B; Maurice C; Nkengasong J; Konan-Koko R; Kadio A; Wiktor S; Lackritz E; Saba J; Chorba T
    AIDS; 2003 Jul; 17 Suppl 3():S5-15. PubMed ID: 14565604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4 count-based failure criteria combined with viral load monitoring may trigger worse switch decisions than viral load monitoring alone.
    Hoffmann CJ; Maritz J; van Zyl GU
    Trop Med Int Health; 2016 Feb; 21(2):219-23. PubMed ID: 26584666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
    Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
    HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.